Clinical Trials Logo

Clostridium Infections clinical trials

View clinical trials related to Clostridium Infections.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06398379 Not yet recruiting - Clinical trials for Clostridium Difficile Infections

Virus as Treatment of C. Difficile Infection (VISION)

VISION
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Fecal Virome Transplantation (FVT) has in small studies shown benefit in the treatment of recurrent C. difficile infection. In the VISION study we will treat patients with recurrent C. difficile infection with FVT capsules and compare the treatment with Fecal Microbiota Transplantation (FMT) capsules. Both will be following af standard treatment of antibiotics (Vancomycin)

NCT ID: NCT06367504 Not yet recruiting - Clinical trials for Clostridium Difficile Infection

A Study to Assess the Effect of Doctor's Biome Medical Food in Individuals With Clostridium Difficile Infection

Start date: July 15, 2024
Phase: N/A
Study type: Interventional

A randomized, double-blind, placebo-controlled, pilot clinical study to assess the effect of Doctor's Biome Medical Food (DBMF) in individuals with Clostridium difficile infection (CDI)

NCT ID: NCT06228352 Not yet recruiting - Ulcerative Colitis Clinical Trials

Role of Bile Acids and Microbiota in Clostridioides Difficile Infection in Ulcerative Colitis

ABRICO
Start date: March 2024
Phase:
Study type: Observational

Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease characterized by chronic inflammation of the colon. Composition of gut microbiota of UC patients is abnormal (dysbiosis). Ulcerative Colitis patients have an increased risk of Clostridioides difficile infection (CDI) and CDI complications (colectomy, death, recurrence). The reason for this increased risk in IBD patients is not fully understood. The decrease in the proportion of secondary bile acids, induced by microbiota dysbiosis in patients with UC could favor C. difficile infection. The main objective of the study is to describe the composition of bile acids (primary and secondary) in children followed for UC during relapse with or without CDI and to compare it to children with UC in remission and healthy controls. The composition of fecal microbiota will be also describe to correlate dysbiosis and bile acid abnormalities. And finally some fecal biomarkers will be study : short chain fatty acids, metabolic pathway of Tryptophan, and fecal Calprotectin.

NCT ID: NCT06107569 Not yet recruiting - Clinical trials for Clostridium Difficile Infections

Treatment of CDI and Recurrence With Fecal Microbiota Transplant Using Promicrobioma

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

The increasing inappropriate use of antimicrobials, in addition to increasing selective pressure and inducing environmental resistance, is also a risk factor for the development of Clostridioides difficile infection (CDI). The intestinal microbiota is mainly composed of the phyla Firmicutes, Bacteroidetes, Acinobacteria, Proteobacteria, Fusobacteria and Verrucomicrobia, and more than 90% of the phylum Firmicutes is composed of Clostridium spp. (two). The inappropriate use of antimicrobials initiates a process of dysregulation of the microbiome, called dysbiosis, and it is from the selection of genera and species of bacteria that will dominate the intestine that pseudomembranous colitis can set in with an increased burden of Clostridioides difficile, a gram positive, anaerobic, spore-forming, that produces two enterotoxins, toxin A and toxin.

NCT ID: NCT05852587 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

Start date: January 1, 2025
Phase: Phase 1
Study type: Interventional

This is a randomized, placebo-controlled, dose-ranging study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients. A total of 99 patients who meet eligibility criteria will be randomized 1:1:1 to one of two xylitol doses or placebo arm. All arms will receive an identical capsule dosing for four weeks. Microbiome assessment and C. difficile testing will be performed at baseline, week 4, 8, 26, and 52.

NCT ID: NCT05606159 Not yet recruiting - Clinical trials for Clostridium Difficile Infection Recurrence

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

Start date: November 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a single strain capsulated probiotic, when used after standard C. difficile antibiotic therapy, is effective in reducing the risk of infection recurrence mediated by a decrease in colonization by toxigenic C. difficile. This study will include adults with a history of two episodes of C. difficile infection (CDI).

NCT ID: NCT05330182 Not yet recruiting - Clinical trials for Clostridioides Difficile Infection

LMN-201 for Prevention of C. Difficile Infection Recurrence

Start date: August 19, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.

NCT ID: NCT05256693 Not yet recruiting - Clinical trials for Stem Cell Transplant Complications

Prevention of C.Difficile Infections With Oral Vancomycine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

VANCALLO
Start date: March 2022
Phase: Phase 3
Study type: Interventional

Clostridium difficile (CD) infection are an important cause of morbi-mortality in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT). The VANCALLO trial aims at evaluating oral vancomycine reducing the risk of CD infection relying on a placebo controlled 1:1 randomized design, including one interim analysis.

NCT ID: NCT04960306 Not yet recruiting - Clinical trials for Clostridium Difficile Infection

Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection

FILTRATE
Start date: November 1, 2023
Phase: Phase 3
Study type: Interventional

Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infectious diseases with a high mortality rate (6-30%). The treatment of CDI, especially the recurrent form of the disease is still considered a challenge. The FILTRATE randomized controlled trial aims to investigate the safety and efficacy of fecal filtrate transplantation in the treatment of recurrent CDI and compare it with conventional fecal microbiota transplantation (FMT).

NCT ID: NCT04567134 Not yet recruiting - Clinical trials for Clostridium Difficile Infection

Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea

Start date: October 1, 2020
Phase:
Study type: Observational

Our objective of this study is to derive a real incidence of CDI in tertiary hospitals located through Korean peninsula. In order to get a close value to the truth, the study is planned to co-perform with a national study which was proposed in evaluation process to include more hospitals. Along with the incidence of CDI, clinical characteristics and outcome of CDI will be examined and microbiologic characteristics of C. difficile isolates from CDI patients are studied.